Volitionrx LTD VNRX
We take great care to ensure that the data presented and summarized in this overview for VOLITIONRX LTD is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VNRX
View all-
Armistice Capital, LLC New York, NY8.48MShares$4.67 Million0.07% of portfolio
-
Lagoda Investment Management, L.P. New York, NY7.58MShares$4.17 Million2.46% of portfolio
-
Geode Capital Management, LLC Boston, MA744KShares$409,1130.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA637KShares$350,1660.0% of portfolio
-
Black Rock Inc. New York, NY516KShares$283,8400.0% of portfolio
-
Cowen Prime Advisors LLC179KShares$98,3050.09% of portfolio
-
State Street Corp Boston, MA148KShares$81,2000.0% of portfolio
-
Silverberg Bernstein Capital Management LLC Armonk, NY141KShares$77,3150.07% of portfolio
-
Northern Trust Corp Chicago, IL118KShares$64,8310.0% of portfolio
-
Ubs Group Ag107KShares$59,0410.0% of portfolio
Latest Institutional Activity in VNRX
Top Purchases
Top Sells
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Insider Transactions at VNRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2025
|
Guy Archibald Innes |
BUY
Open market or private purchase
|
Direct |
181,818
+17.31%
|
$0
$0.55 P/Share
|
|
Mar 26
2025
|
Cameron John Reynolds President and CEO |
BUY
Open market or private purchase
|
Direct |
181,818
+7.33%
|
$0
$0.55 P/Share
|
|
Mar 01
2025
|
Terig Hughes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,969
+3.46%
|
-
|
|
Mar 01
2025
|
Guy Archibald Innes |
BUY
Grant, award, or other acquisition
|
Direct |
19,786
+2.8%
|
-
|
|
Mar 01
2025
|
Gael Forterre Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,523
+3.28%
|
-
|
|
Mar 01
2025
|
Salvatore Thomas Butera CEO - Volition Veterinary |
BUY
Grant, award, or other acquisition
|
Direct |
19,300
+5.81%
|
-
|
|
Mar 01
2025
|
Ethel Rubin |
BUY
Grant, award, or other acquisition
|
Direct |
9,893
+22.78%
|
-
|
|
Mar 01
2025
|
Andrew Retter Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,142
+6.86%
|
-
|
|
Mar 01
2025
|
Jasmine Kway CEO - Singapore Volition |
BUY
Grant, award, or other acquisition
|
Direct |
16,708
+8.38%
|
-
|
|
Mar 01
2025
|
Alan Colman |
BUY
Grant, award, or other acquisition
|
Direct |
14,840
+5.7%
|
-
|
|
Mar 01
2025
|
Ann Louise Batchelor Group Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,233
+9.94%
|
-
|
|
Mar 01
2025
|
Kim Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
9,893
+10.27%
|
-
|
|
Mar 01
2025
|
Nicholas Plummer GC - Volition Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
12,483
+6.57%
|
-
|
|
Mar 01
2025
|
Rodney Gerard Rootsaert Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
7,908
+5.24%
|
-
|
|
Jan 15
2025
|
Guy Archibald Innes |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+6.97%
|
-
|
|
Dec 09
2024
|
Cameron John Reynolds President and CEO |
BUY
Open market or private purchase
|
Direct |
139,811
+6.19%
|
$0
$0.57 P/Share
|
|
Dec 09
2024
|
Jacob Vincent Micallef Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
43,691
+9.97%
|
$0
$0.57 P/Share
|
|
Dec 09
2024
|
Timothy I Still |
BUY
Open market or private purchase
|
Direct |
87,382
+5.55%
|
$0
$0.57 P/Share
|
|
Dec 09
2024
|
Guy Archibald Innes |
BUY
Open market or private purchase
|
Direct |
174,764
+22.07%
|
$0
$0.57 P/Share
|
|
Dec 01
2024
|
Salvatore Thomas Butera CEO - Volition Veterinary |
BUY
Grant, award, or other acquisition
|
Direct |
16,871
+5.43%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.71M shares |
|---|---|
| Bona fide gift | 400K shares |
| Open market or private purchase | 959K shares |
| Bona fide gift | 400K shares |
|---|---|
| Payment of exercise price or tax liability | 77.1K shares |